Plant-produced chimeric virus-like particles - a new generation vaccine against African horse sickness.
Authors: Rutkowska Daria A, Mokoena Nobalanda B, Tsekoa Tsepo L, Dibakwane Vusi S, O'Kennedy Martha M
Journal: BMC veterinary research
Summary
# Editorial Summary: Plant-Produced VLP Vaccine Against African Horse Sickness African horse sickness remains a devastating equine disease with mortality rates reaching 95% in naïve populations, yet current live attenuated vaccines present significant safety constraints that limit their deployment and acceptance. Rutkowska and colleagues explored an innovative alternative by developing chimeric virus-like particles (VLPs) using transient plant-based expression systems—a platform that offers rapid scalability and production advantages over traditional vaccine manufacturing methods. Their research demonstrated that plant-derived VLPs could effectively replicate the antigenic properties of AHSV whilst circumventing the safety liabilities associated with live vaccine administration. For equine practitioners in endemic regions and those managing international movement of horses, this work represents meaningful progress toward a safer immunisation strategy that could significantly improve disease control protocols. The scalability of plant-based production is particularly relevant for developing countries where AHS poses greatest economic and welfare concerns, potentially enabling more accessible vaccination campaigns and reducing reliance on expensive, logistically challenging cold-chain infrastructure.
Read the full abstract on PubMed
Practical Takeaways
- •AHS remains a critical disease threat in endemic regions with catastrophic mortality; improved vaccine safety profiles could expand vaccination options
- •Plant-produced VLP vaccines represent an emerging technology that may provide safer immunity than current live vaccines without sacrificing efficacy
- •Keep informed on VLP vaccine development progress as it may offer better risk-benefit profiles for high-risk equine populations in AHS-endemic areas
Key Findings
- •African horse sickness has mortality rates up to 95% in naive susceptible horses and represents a severe arthropod-borne viral threat to equids
- •Current live attenuated AHS vaccines present safety concerns that drive need for alternative vaccination strategies
- •Plant-based expression systems offer rapid, scalable production of virus-like particles (VLPs) as a safer alternative vaccine platform for AHSV